Solidarity Trial
-
Global COVID-19 treatment trial shows current antivirals are of little benefit to hospitalized patients
Interim results from the Solidarity Therapeutics Trial indicate that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.
-
Canadian hospitals trialing new treatment options for COVID-19 patients
Hospitals across Canada are leading a research effort examining potential treatments for COVID-19 as part of the Solidarity Trial, a multinational initiative being coordinated by the World Health Organization (WHO) and supported by the Canadian Institutes of Health Research (CIHR).